NZ591394A - Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers - Google Patents

Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Info

Publication number
NZ591394A
NZ591394A NZ591394A NZ59139409A NZ591394A NZ 591394 A NZ591394 A NZ 591394A NZ 591394 A NZ591394 A NZ 591394A NZ 59139409 A NZ59139409 A NZ 59139409A NZ 591394 A NZ591394 A NZ 591394A
Authority
NZ
New Zealand
Prior art keywords
diazenyl
dimethylamino
carboxamide
thiophene
triazin
Prior art date
Application number
NZ591394A
Other languages
English (en)
Inventor
Ganga Raju Gokaraju
Sudhakar Kasina
Rama Raju Gokaraju
Trimurtulu Golakoti
Venkateswarlu Somepalli
Sengupta Krishanu
Kiran Bhupathiraju
Original Assignee
Kasina Laila Innova Pharmaceuticals Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kasina Laila Innova Pharmaceuticals Private Ltd filed Critical Kasina Laila Innova Pharmaceuticals Private Ltd
Publication of NZ591394A publication Critical patent/NZ591394A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40Thiophene-2-carboxylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NZ591394A 2008-09-15 2009-09-14 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers NZ591394A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2230CH2008 2008-09-15
PCT/IN2009/000504 WO2010029577A2 (en) 2008-09-15 2009-09-14 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Publications (1)

Publication Number Publication Date
NZ591394A true NZ591394A (en) 2013-03-28

Family

ID=41565903

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ591394A NZ591394A (en) 2008-09-15 2009-09-14 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Country Status (11)

Country Link
US (1) US8258119B2 (enExample)
EP (1) EP2324006B1 (enExample)
JP (1) JP2012502900A (enExample)
KR (1) KR20110063537A (enExample)
CN (1) CN102149703B (enExample)
AU (1) AU2009290365B2 (enExample)
BR (1) BRPI0913485A2 (enExample)
CA (1) CA2736732A1 (enExample)
IL (1) IL211366A0 (enExample)
NZ (1) NZ591394A (enExample)
WO (1) WO2010029577A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1006651A2 (pt) * 2009-04-27 2015-08-25 Kasina Laila Innova Pharmaceuticals Private Ltd Medicamentos anticancer e usos relacionados para melanome maligno e outros canceres
NO2686520T3 (enExample) 2011-06-06 2018-03-17
CA2837560C (en) * 2011-06-06 2017-02-14 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
PE20160194A1 (es) 2013-06-13 2016-04-20 Akebia Therapeutics Inc Composiciones y metodos para tratar anemia
US9593095B2 (en) 2013-06-14 2017-03-14 Duke University Methods for the treatment of bacterial infections
DE112014006766T5 (de) 2014-06-27 2017-04-27 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Herstellung und medizinische Verwendung von Triazenen
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
SG11201707994UA (en) 2015-04-01 2017-10-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
WO2016187191A1 (en) 2015-05-18 2016-11-24 Medoc Pharmaceutical Co., Ltd. A pharmaceutical co-crystal and use thereof
CA2988989A1 (en) 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Composition containing carboplatin and use
WO2016205785A1 (en) 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
JP6929234B2 (ja) 2015-06-25 2021-09-01 シン−ナット プロダクツ エンタープライズ エルエルシー 医薬共結晶組成物及びその用途
AU2019265629B2 (en) 2018-05-09 2024-09-12 Akebia Therapeutics, Inc. Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid
KR102648781B1 (ko) 2021-11-09 2024-03-19 국립공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1020641B (de) 1955-10-15 1957-12-12 Basf Ag Verfahren zur Herstellung von Derivaten der 3-Oxythiophen-2-carbonsaeure
CA968347A (en) * 1968-09-09 1975-05-27 John F. Gerster Substituted pyrazoles and process

Also Published As

Publication number Publication date
AU2009290365B2 (en) 2014-08-14
CN102149703B (zh) 2014-09-10
AU2009290365A1 (en) 2010-03-18
WO2010029577A3 (en) 2010-05-06
KR20110063537A (ko) 2011-06-10
JP2012502900A (ja) 2012-02-02
CN102149703A (zh) 2011-08-10
CA2736732A1 (en) 2010-03-18
US20100068178A1 (en) 2010-03-18
EP2324006B1 (en) 2014-08-13
US8258119B2 (en) 2012-09-04
EP2324006A2 (en) 2011-05-25
IL211366A0 (en) 2011-04-28
WO2010029577A2 (en) 2010-03-18
BRPI0913485A2 (pt) 2016-06-07

Similar Documents

Publication Publication Date Title
NZ591394A (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
HRP20110841T1 (hr) Korisni monobaktamski antibiotici
NZ594122A (en) 2-Phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide derivatives
IL189069A0 (en) Piperidine and piperazine derivatives as p2x3 antagonists
HRP20100677T1 (hr) IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2
WO2009005152A1 (ja) 新規脂質トリペプチド性ヒドロゲル化剤及びヒドロゲル
CA2493995A1 (en) Macrolide compounds endowed with antiinflammatory activity
ME01294B (me) Nova jedinjenja i kompozicije i metode upotrebe
DE60228406D1 (de) PYRAZOLOÄ3,4-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN DES PURINERGEN REZEPTORS
AR057894A1 (es) Derivados de tiofeno
JP2009515980A5 (enExample)
MX2009007954A (es) Derivado de heterocicliden-n-(aril) acetamida.
JP2012502900A5 (enExample)
CA2521732A1 (en) Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
CA2502347A1 (en) 9a-azalides with anti-inflammatory activity
MX2015008479A (es) Compuesto heterociclico sustituido con halogeno.
DE150507T1 (de) Cephalosporinverbindungen, verfahren zu ihrer herstellung und pharmazeutishe praeparate.
WO2004063330A3 (en) (2-carboxamido) (3-amino) thiophene compounds
JP2005538042A5 (enExample)
NZ586650A (en) Inhibitors of iap
AU2003207432A1 (en) Urea linker derivatives for use as ppar modulators
WO2009001730A1 (ja) βセクレターゼ阻害活性を有する新規化合物
JP2005502687A5 (enExample)
HRP20100622T8 (en) New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them
NZ337608A (en) Partial reduction of doubles bonds of five membered ring does not occur when using Al as reducing agent so 5-{4-[2-(5-methyl-2-phenyloxazol-4-yl)-ethoxy]-naphth-1-ylmethyl}-thiazolidine-2,4-dione reduced to 5-{4-[2-(5-methyl-2-phenyloxazo-4-yl)-ethoxy]-naphth-1-ylmethylidene}-thiazolidine-2,4-dione

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 SEP 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20130930

LAPS Patent lapsed